- 1001. antibody conjugate
- [ ] (UMLS (CSP) C0598658) =Immunologic Factor; Indicator, Reagent, or Diagnostic Aid ;
| - 1051. Antiflatulent Agent
- [Natural or synthetic compounds usually administered orally, Antiflatulent Agents relieve or prevent flatulence, excess gas in the stomach and intestines, by adsorbing the gas, stimulating intestinal elimination of gas, or preventing gas formation. Alpha-galactosidase and activated charcoal are used against flatulence. (NCI04) ( NCI )] (UMLS (NCI) C0003305) =Pharmacologic Substance ;
|
- 1002. Antibody Conjugate Therapy
- (UMLS (NCI) C0280026) =Therapeutic or Preventive Procedure
| - 1052. antifoaming agent
- [Agents used to prevent the formation of foam or to treat flatulence or bloat. ( MSH )] (UMLS (CSP) C0003306) =Chemical Viewed Functionally ;
|
- 1003. antibody deficiency syndrome
- [ ] (UMLS (CSP) C0003257) =Disease or Syndrome ;
| - 1053. antifolate
- [inhibitors of the enzyme, dihydrofolate reductase, which converts dihydrofolate to tetrahydrofolate; frequently used in cancer chemotherapy. ( CSP )] (UMLS (NCI) C0016411) =Pharmacologic Substance =antimetabolite;
Inhibitors, Nucleic Acid Synthesis;
vitamin antagonist;
=4-Aminofolic acid;
4-Amino-10-methylfolic Acid;
Thymidylate Synthase Inhibitor;
DHFR Inhibitor;
|
- 1004. antibody dependent killer cell
- [similar to natural killer cells except cytotoxic action requires triggering by antibody coating of target cells, mediated by Fc receptors; may be derived from lymphocytes, polymorphs, eosinophils, or monocytes/macrophages. ( CSP )] (UMLS (CSP) C0596108) =Cell ;
=K cell;
| - 1054. antifreeze
- [ ] (UMLS (CSP) C0598248) =Substance ;
|
- 1005. antibody diversity
- [The phenomenon of immense variability characteristic of ANTIBODIES. It enables the IMMUNE SYSTEM to react specifically against the essentially unlimited kinds of ANTIGENS it encounters. Antibody diversity is accounted for by three main theories: (1) the Germ Line Theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; (2) the Somatic Mutation Theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and (3) the Gene Rearrangement Theory, which holds that antibody diversity is generated by the rearrangement of IMMUNOGLOBULIN VARIABLE REGION gene segments during the differentiation of the ANTIBODY-PRODUCING CELLS. ( MSH )] (UMLS (CSP) C0003259) =Molecular Function ;
| - 1055. antifungal antibiotic
- [antibiotics inhibiting the growth of or killing fungi and used in the treatment of various fungal diseases. ( CSP )] (UMLS (CSP) C0003235) =Antibiotic ;
|
- 1006. antibody formation
- [synthesis of antibodies in response to B-cell activation by antigens; includes genetic regulation, recombination, all aspects of gene expression of the antibodies as well as the proliferation and differentiation of the B lymphocytes into plasma cells or memory cells. ( CSP )] (UMLS (CSP) C0003261) =Biologic Function ;
| - 1056. antifungal antibody
- [immunoglobulins induced by exposure to fungal antigens. ( CSP )] (UMLS (CSP) C0003245) =Amino Acid, Peptide, or Protein; Immunologic Factor
|
- 1007. antibody hypersensitivity
- [ ] (UMLS (CSP) C0598650) =Pathologic Function
| - 1057. Antifungal Therapy
- (UMLS (NCI) C0678026) =Therapeutic or Preventive Procedure ;
|
- 1008. antibody inhibitor
- [any substance or state which suppresses, prevents or opposes the actions of infection-fighting protein molecules in blood or secretory fluids known as antibodies. ( CSP )] (UMLS (CSP) C0178481) =Immunologic Factor =inhibitor/antagonist;
| - 1058. antigen
- [any substance recognized by the immune system and inducing an immune reaction. ( CSP )] (UMLS (CSP) C0003320) =Immunologic Factor
|
- 1009. antibody neutralization test
- [titration of an antiserum by testing a series of dilutions of virus or immune serum to a given end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). ( CSP )] (UMLS (CSP) C0027944) =Laboratory Procedure =serology/serodiagnosis;
| - 1059. Antigen AC133
- [Prominin-1 protein (865 aa, ~97 kDa) is encoded by the KIF4A gene. This protein may play a role in hematopoiesis, but an exact function has yet to be elucidated. The protien has been implicated in tumor pathogenesis and formation in several cancers, including retinoblastoma, hemangioma, and glioblastoma phenotypes. Additionally, the protein has been used as a marker to distinguish cells that have the potential to become cancerous from the larger normal cell population. ( NCI )] (UMLS (NCI) C0673028) =Amino Acid, Peptide, or Protein; Immunologic Factor ;
|
- 1010. antibody positive AIDS test
- [Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). ( MSH )] (UMLS (CSP) C0019699) =Finding ;
=HIV Infection;
| - 1060. antigen antibody affinity
- [A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes. ( MSH )] (UMLS (CSP) C0003255) =Molecular Function ;
|
- 1011. Antibody Producing Cell
- [Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. (MeSH) ( NCI )] (UMLS (NCI) C0003273) =Cell ;
| - 1061. antigen antibody binding
- [ ] (UMLS (CSP) C0597878) =Molecular Function ;
|
- 1012. antibody receptor
- [family of cell surface molecules which mediate the specific intracellular effects of antibody binding, usually by the Fc region; do not confuse with other antibody-binding moieties which are normally antigens that bind to the Fab region. ( CSP )] (UMLS (CSP) C0034805) =Amino Acid, Peptide, or Protein; Immunologic Factor; Receptor =Receptor;
| - 1062. antigen antibody complex
- [product of an antigen antibody reaction; may also contain complement. ( CSP )] (UMLS (CSP) C0003313) =Amino Acid, Peptide, or Protein; Immunologic Factor
|
- 1013. antibody specificity
- [property of antibodies which enables them to react with some antigenic determinants and not with others; specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. ( CSP )] (UMLS (CSP) C0003264) =Molecular Function ;
| - 1063. antigen antibody reaction
- [immune response induced by binding antigen to antibody. ( CSP )] (UMLS (CSP) C0003314) =Molecular Function ;
|
- 1014. Antibody T-101, Monoclonal
- [A murine monoclonal antibody (MoAb) with application in Immunotherapy and radioimmunodetection in T-cell malignancies. MoAb T101 recognizes a 65kD glycoprotein, CD5 antigen, on the surface of T-cells. When radiolabeled, this MoAb has potential use in the radioimaging or may induce a cytotoxic T-cell response against CD5+ T cells. ( NCI )] (UMLS (NCI) C0280031) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 1064. Antigen Binding
- [Antigen Binding Interaction involves specific and high affinity non-covalent interaction (binding) of an endogenous antibody through intermolecular physical forces of attraction and spatial complementarity with a soluble or particulate substance (antigen) that induces an immune response. ( NCI )] (UMLS (NCI) C1148575) =Molecular Function ;
|
- 1015. Antibody Therapy
- [Treatment with an antibody, a substance that can directly kill specific tumor cells or stimulate the immune system to kill tumor cells. ( NCI )] (UMLS (NCI) C0281176) =Therapeutic or Preventive Procedure ;
| - 1065. Antigen Binding Fragment
- [Part of an immunoglobulin antibody that binds a specific antigen and consists of both a light chain and part of a heavy chain. By comparison, natural antibodies consist of two heavy and two light chains. An FAB (fragment antibody) offers the advantages of smaller size and lower cross-reactivity compared to the complete antibody. (NCI04) ( NCI )] (UMLS (NCI) C0021031) =Amino Acid, Peptide, or Protein; Immunologic Factor ;
=Immunoglobulin Fragments;
=abciximab |
- 1016. antibody titering
- [determination of the concentration of an antibody relative to antigens in a sample by adding a standard solution to a test sample and calculating the composition from the end point. ( CSP )] (UMLS (CSP) C0474643) =Laboratory Procedure ;
=immunologic assay;
| - 1066. Antigen CD61
- [Widely expressed by human ITGB3 Gene (ITGB Family), type I membrane protein Integrin Beta 3 contains a VWFA-like domain and is involved in cell adhesion and signaling. Multiple heterodimeric alpha/beta combinations result in different integrins. ITGB3 associates with alphaIIB or alphaV and recognize RGD; aIIB/beta-3 also recognizes HHLGGGAKQAGDV in FN gamma. Beta-3C interacts with FLNB. aV/beta-3 is a receptor for cytotactin, fibronectin, laminin, MMP-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin, and von Willebrand factor. Receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin, and vitronectin, aIIB/beta-3 binds fibrinogen to induce platelet aggregation and plug ruptured endothelia. In response to platelet aggregation, Tyr-773/785 phosphorylated ITGB3 appears to bind GRB2/SHC. ITGB3 defects cause Glanzmann thrombasthenia (GT). (NCI) ( NCI )] (UMLS (NCI) C0638262) =Amino Acid, Peptide, or Protein; Receptor
|
- 1017. antibody treated bone marrow transplant
- (UMLS (NCI) C0279022) =Therapeutic or Preventive Procedure
| - 1067. Antigen CD82
- [Kangai 1 Protein, a metastasis suppressor protein encoded by the 80 kb human KAI1 gene (TM4SF family), is expressed in many tissues and has four putative transmembrane domains and a large extracellular domain having three potential N-glycosylation sites. KAI1 appears to be up regulated in activated T-cells. p53 activates the gene by interacting with sequences in a 5-prime upstream region. Loss of p53 appears to cause down-regulation of KAI1. Similar to leukocyte cell surface glycoproteins involved in cell adhesion and signal transduction, KAI1 is a likely homologue of mouse leukocyte surface antigen R2. Associated with CD4 or CD8, KAI1 delivers co-stimulatory signals for the TCR/CD3 pathway. KAI1 expression at the transcription or posttranscription level is often down regulated during tumor progression. (from SWISS-PROT, OMIM, and NCI) ( NCI )] (UMLS (NCI) C0286983) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
|
- 1018. Antibody-Mediated Lympholysis
- [The cytotoxicity of cells depending on antibody recognition. The killing of a target cell by a killer cell by means of an antibody directed to the target by the antigen-binding arms and anchored to the killer cell via an Fc receptor. ( NCI )] (UMLS (NCI) C0301895) =Cell Function ;
| - 1068. antigen challenge
- [ ] (UMLS (CSP) C0597750) =Therapeutic or Preventive Procedure ;
|
- 1019. Anticachectic Therapy
- [Treatment to manage or alleviate the fatigue and weight loss often associated with cancer. ( NCI )] (UMLS (NCI) C0279840) =Therapeutic or Preventive Procedure
| - 1069. Antigen Identified by Monoclonal Antibody Ki-67
- [Antigen Identified by Monoclonal Antibody Ki-67, encoded by the MKI67 gene, is a nuclear antigen expressed in proliferating cells but not in quiescent cells, and required for maintaining cell proliferation. Expression of this antigen occurs preferentially during late G1, S, G2, and M phases of the cell cycle, while in cells in G0 phase the antigen cannot be detected. Consequently, the monoclonal antibody Ki-67 is used in tumor pathology to detect proliferating cells in neoplastic diseases. This antigen is located in the nucleus, predominantly localized in the G1 phase in the perinucleolar region. In the later phases it is also detected throughout the nuclear interior, being predominantly localized in the nuclear matrix. In mitosis, it is present on all chromosomes. This antigen contains 1 FHA domain. Two alternative splicing forms exist, Long and Short. (from Swiss-Prot) ( NCI )] (UMLS (NCI) C0208804) =Amino Acid, Peptide, or Protein; Immunologic Factor; Indicator, Reagent, or Diagnostic Aid
|
- 1020. Anticancer Drugs
- (UMLS (HL7) C1548818) =Health Care Activity =Consent Type;
| - 1070. Antigen Identified by Monoclonal Antibody Ki-67 Gene
- [This gene is involved in cellular proliferation. ( NCI )] (UMLS (NCI) C1334508) MKI67;
MKI67 Gene;
=Gene or Genome ;
|
- 1021. Anticholinergic Agent
- [group of drugs that bind to but do not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists. ( CSP )] (UMLS (NCI) C0242896) =Pharmacologic Substance ;
=neuropharmacologic agent;
neurotransmitter antagonist =atropine;
PROMAZINE;
1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-,(-)-tropate(ester) | - 1071. Antigen LB39-AA
- [Expressed in melanocytes and retina by human MLANA Gene, 118-aa 13-kDa Pro-rich Melan-A Protein is an antigen recognized by cytolytic T lymphocytes that contains no leader sequence but has a putative transmembrane hydrophobic stretch, that may bind HLA-A2, followed by 3 Arg residues. (NCI) ( NCI )] (UMLS (NCI) C0385723) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
|
- 1022. Anticipatory Nausea and Vomiting
- (UMLS (NCI) C0279036) =Finding
| - 1072. antigen presentation
- [process by which an antigen is presented to lymphocytes in a form they can recognize; antigen presenting cells may ingest or digest the antigen and present the fragments to the cell surface for recognition by the lymphocytes. ( CSP )] (UMLS (CSP) C0206431) =Cell Function =immune modulation;
=leukocyte activation/transformation;
lymphocyte proliferation |
- 1023. Anticipatory Vomiting
- [Vomiting caused by expectation of discomfort or unpleasantness. ( MSH )] (UMLS (NCI) C0042964) =Sign or Symptom =Braken;
| - 1073. Antigen Processing
- [The process by which foreign molecules are taken up by antigen presenting cells, proteolytically cleaved, and displayed on the cell surface in complex with MHC molecules. ( NCI )] (UMLS (NCI) C0206430) =Cell Function
|
- 1024. Anticoagulation
- [Events or activities that prevent or inhibit coagulation. ( NCI )] (UMLS (NCI) C0003281) =Therapeutic or Preventive Procedure ;
| - 1074. Antigen Proliferation Assay
- [An in vitro test of T-cell function ( NCI )] (UMLS (NCI) C0201614) =Laboratory Procedure
|
- 1025. Anticoagulation Therapy
- (UMLS (NCI) C0741135) Anticoagulation Treatment =Therapeutic or Preventive Procedure ;
| - 1075. antigen receptor
- [family of immunoglobin-like lymphocyte surface molecules that mediate activation of lymphocytes by antigens. ( CSP )] (UMLS (CSP) C0034788) =Amino Acid, Peptide, or Protein; Immunologic Factor; Receptor =Cytoplasmic Receptor;
=B cell receptor;
Major Histocompatibility Complex Receptor;
|
- 1026. Anticode G3139
- (UMLS (NCI) C1144384) bcl-2 antisense oligodeoxynucleotide G3139;
BCL-2 Antisense/G3139;
G3139;
G3139 Antisense Oligonucleotide;
G3139 BCL-2 Antisense Oligo;
G3139 BCL-2 Antisense Oligodeoxynucleotide;
G3139 BCL-2 Antisense Oligonucleotide;
=Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
| - 1076. antigen registry
- [ ] (UMLS (CSP) C1331067) =Health Care Related Organization
|
- 1027. Anticonvulsant Therapy
- (UMLS (NCI) C0521306) =Therapeutic or Preventive Procedure
| - 1077. antigen resource
- [ ] (UMLS (CSP) C1331068) =Health Care Related Organization
|
- 1028. Anticonvulsants affecting fetus or newborn via placenta or breast milk
- [ ] (UMLS (ICD9CM) C1561781) MAT ANTICONV AFF NB/FET;
=Pathologic Function | - 1078. antigen specificity
- [ ] (UMLS (CSP) C1536991) =Molecular Function
|
- 1029. Anticonvulsants and anti-Parkinsonism drugs causing adverse effects in therapeutic use
- [ ] (UMLS (ICD9CM) C0481142) =Injury or Poisoning
| - 1079. antigen, gp209-2m
- [A modified peptide antigen derived from gp209, with potential immunomodulatory and antineoplastic activities. gp209-2M antigen (IMDQVPFSV) has a methionine substitution of threonine at position 2 of gp209 peptide (ITDQVPFSV), which is the immunogenic epitope of human melanoma tumor glycoprotein gp100. Vaccination with this peptide may evoke a cytotoxic T lymphocyte (CTL) response against tumor cells expression the gp100 antigen. ( NCI )] (UMLS (NCI) C0338352) =Pharmacologic Substance; Immunologic Factor
|
- 1030. ANTIDEPRESS ABUSE-CONTIN
- [ ] (UMLS (ICD9CM) C0154541) =Mental or Behavioral Dysfunction
| - 1080. Antigen, Prostate-Specific
- [PSA. A substance produced by the prostate that may be found in an increased amount in the blood of men who have prostate cancer, benign prostatic hyperplasia, or infection or inflammation of the prostate. ( NCI )] (UMLS (NCI) C0138741) =Amino Acid, Peptide, or Protein; Enzyme; Immunologic Factor =kallikrein;
|
- 1031. ANTIDEPRESS ABUSE-EPISOD
- [ ] (UMLS (ICD9CM) C0154542) =Mental or Behavioral Dysfunction
| - 1081. Antigen, Thomsen-Friedenreich
- [A type 1 core O-glycan with potential immunotherapeutic property. Thomsen-Friedenreich (TF) antigen, a galactose disaccharide, is normally O-linked to serine or threonine residue of mucins (MUC1), a transmembrane glycoprotein overexpressed on epithelial cell surface of a variety of tumor cells. The expression of this antigen is associated with tumor cell adhesion, tissue invasion and aggressiveness. When administered in a vaccine formulation, TF antigen may stimulate a cytotoxic T cell response against tumors expressing TF epitope, which may result in a reduction in tumor size. ( NCI )] (UMLS (NCI) C0053438) =Immunologic Factor
|
- 1032. ANTIDEPRESS ABUSE-REMISS
- [ ] (UMLS (ICD9CM) C0154543) =Mental or Behavioral Dysfunction
| - 1082. antigenic determinant
- [The simplest form of an antigenic determinant, on a complex antigenic molecule, which can combine with antibody or T cell receptor. ( NCI )] (UMLS (CSP) C0003316) =Immunologic Factor
|
- 1033. ANTIDEPRESS ABUSE-UNSPEC
- [ ] (UMLS (ICD9CM) C0375185) =Mental or Behavioral Dysfunction
| - 1083. antigenic peptide transporter
- [transmembrane transporters located as a complex anchored in the endoplasmic reticulum membrane; functions as an ATP dependent peptide pump to convey short peptides into the endoplasmic reticulum. ( CSP )] (UMLS (CSP) C0597880) =Amino Acid, Peptide, or Protein; Biologically Active Substance =membrane transport protein;
|
- 1034. Antidepressant type abuse
- [ ] (UMLS (ICD9CM) C0154540) =Mental or Behavioral Dysfunction
| - 1084. Antigenic Surface Determinant Protein OA3
- [CD47 Antigen, encoded by the CD47 gene, is a 50-kD membrane protein with an amino-terminal immunoglobulin domain and a carboxyl-terminal multiple-membrane-spanning region. CD47 Antigen is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix. It is also involved in membrane permeability changes induced following virus infection. Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. The interaction of CD47 with SHPS-1 may contribute to the recruitment of B lymphocytes via endothelial cells under steady state conditions. CD47 Antigen is very broadly distributed on normal adult tissues, as well as ovarian tumors, being especially abundant in some epithelia and the brain. Four isoforms are produced by alternative splicing. (From LocusLink, OMIM, Swiss-Prot and NCI) ( NCI )] (UMLS (NCI) C0220248) =Amino Acid, Peptide, or Protein; Immunologic Factor =CD antigen;
|
- 1035. antidiabetic
- [By supplying insulin or stimulating endogenous insulin production, natural or synthetic Anti-diabetic Agents relieve diabetes, reducing and controlling blood sugar levels. Most current insulin products are obtained by recombinant DNA technology and mimic natural insulin. Oral hypoglycemic agents that stimulate pancreatic insulin production and increase glucose uptake in various tissues mainly belong to sulfonylurea and biguanide classes. (NCI04) ( NCI )] (UMLS (CSP) C0935929) Anti-diabetic Agent;
=Pharmacologic Substance | - 1085. antiglaucoma drug
- [agent used to reduce elevated intraocular pressure. ( CSP )] (UMLS (CSP) C0597128) =Pharmacologic Substance ;
=[OP000] OPHTHALMIC AGENTS;
=forskolin;
|
- 1036. Antidiabetic Hormone
- [pancreatic hormone secreted by the alpha cells of the pancreatic islets; a 29-amino acid straight chain polypeptide that plays an important role in regulation of blood glucose concentration, ketone metabolism, and several other biochemical and physiological processes. ( CSP )] (UMLS (NCI) C0017687) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Neuroreactive Substance or Biogenic Amine; Hormone =neuropeptide;
pancreas hormone;
Peptides;
[HS503] ANTIHYPOGLYCEMICS =GLUCAGON 10 MG;
GLUCAGON 1 MG;
| - 1086. antiglobulin test
- [Hemagglutination test in which Coombs' reagent (antiglobulin, or anti-human globulin rabbit immune serum) is added to detect incomplete (non-agglutinating, univalent, blocking) antibodies coating erythrocytes. The direct test is applied to red cells which have been coated with antibody in vivo (e.g., in hemolytic disease of newborn, autoimmune hemolytic anemia, and transfusion reactions). The indirect test is applied to serum to detect the presence of antibody (e.g., in detection of incompatibility in cross-matching tests, detection and identification of irregular antibodies, and in detection of antibodies not identifiable by other means). (MeSH) ( NCI )] (UMLS (CSP) C0009961) =Laboratory Procedure
|
- 1037. Antidiabetic Hormone
- [The recombinant form of the endogenous polypeptide hormone Glucagon consisting of 29 amino acids responsible for the release of stored glucose, causing increased blood glucose levels. Clinical Use: Diagnostic Aid for Imaging Studies and Hypoglycemia. ( NCI )] (UMLS (NCI) C0876232) Glucagon;
glucagon (rDNA);
Hyperglycemic Glycogenolytic Factor;
Recombinant Glucagon =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Hormone | - 1087. Antihaemophilic Factor
- [antihemophilic factor that is part of the factor VIII/von Willebrand factor complex; produced in the liver and acts in the intrinsic pathway of blood coagulation; serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. ( CSP )] (UMLS (NCI) C0015506) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Biologically Active Substance =Blood Coagulation Factor;
Antihaemophilic Factor =Antihaemophilic Factor;
ANTIHEMOPHILIC FACTOR,HUMAN;
Antihemophilic factor, porcine;
ANTIHEMOPHILIC FACTOR,HUMAN,METHOD M,MONOCLONAL;
ANTIHEMOPHILIC FACTOR,RECOMBINANT;
|
- 1038. antidiuresis
- [ ] (UMLS (CSP) C0232826) =Disease or Syndrome
| - 1088. Antihelix
- (UMLS (NCI) C0229308) =Body Part, Organ, or Organ Component
|
- 1039. antidiuretic
- [agent that suppresses urine formation. ( CSP )] (UMLS (CSP) C0596110) =Pharmacologic Substance ;
=Drug;
| - 1089. antihemophilic factor B
- [Factor ix is a vitamin k-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor x to its active form in the presence of ca(2+) ions, phospholipids, and factor VIIIa. ( NCI )] (UMLS (CSP) C0015491) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Biologically Active Substance =Blood Coagulation Factor;
Serine Endopeptidases;
[BL500] BLOOD DERIVATIVES;
=FACTOR IX COMPLEX,HUMAN;
FACTOR IX,RECOMBINANT;
FACTOR IX COMPLEX,HUMAN;
|
- 1040. antidiuretic hormone defective syndrome
- [A genetic or acquired polyuric disorder caused by a deficiency of VASOPRESSINS secreted by the NEUROHYPOPHYSIS. Clinical signs include the excretion of large volumes of dilute URINE; HYPERNATREMIA; THIRST; and polydipsia. Etiologies include HEAD TRAUMA; surgeries and diseases involving the HYPOTHALAMUS and the PITUITARY GLAND. This disorder may also be caused by mutations of genes such as ARVP encoding vasopressin and its corresponding neurophysin (NEUROPHYSINS). ( MSH )] (UMLS (CSP) C0687720) =Disease or Syndrome ;
=diabetes insipidus;
| - 1090. antihemophilic factor C
- [Stable blood coagulation factor involved in the intrinsic pathway. The activated form XIa activates factor IX to IXa. Deficiency of factor XI is often called hemophilia C. ( MSH )] (UMLS (CSP) C0015522) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
=Blood Coagulation Factor;
Serine Endopeptidases |
- 1041. Antidiuretic Hormone Receptor 1A
- [This protein acts as receptor for arginine vasopressin. This receptor belongs to the subfamily of G-protein coupled receptors which includes AVPR1B, V2R and OXT receptors. Its activity is mediated by G proteins which stimulate a phosphatidylinositol-calcium second messenger system. The receptor mediates cell contraction and proliferation, platelet aggregation, release of coagulation factor and glycogenolysis. ( NCI )] (UMLS (NCI) C0284725) =Amino Acid, Peptide, or Protein; Receptor
| - 1091. Antihistamine
- [Any agent that bind to the histamine-1 (H-1) receptor, thereby antagonizing histamine mediated allergic reactions, such as bronchoconstriction, vasodilation and up-regulated capillary permeability. ( NCI )] (UMLS (NCI) C0019592) =Pharmacologic Substance ;
=Histamine Antagonists;
|
- 1042. Antidiuretic Hormone Receptor 1B
- [This protein acts as receptor for arginine vasopressin. This receptor belongs to the subfamily of G-protein coupled receptors which includes AVPR1A, V2R and OXT receptors. Its activity is mediated by G proteins which stimulate a phosphatidylinositol-calcium second messenger system. The receptor is primarily located in the anterior pituitary, where it stimulates ACTH release. It is expressed at high levels in ACTH-secreting pituitary adenomas as well as in bronchial carcinoids responsible for the ectopic ACTH syndrome. A spliced antisense transcript of this gene has been reported but its function is not known. ( NCI )] (UMLS (NCI) C0284726) =Amino Acid, Peptide, or Protein; Receptor
| - 1092. Antihormone Agents
- [substance or agent which suppresses, prevents or opposes the actions of hormones. ( CSP )] (UMLS (NCI) C0019927) =Pharmacologic Substance ;
=inhibitor/antagonist;
=Androgen Antagonists;
Antiestrogen;
insulin inhibitor;
(aa Beta, 17 beta)-11-[4-(dimethylamino)-phenyl]-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one;
prostaglandin inhibitor;
[HS852] ANTITHYROID AGENTS;
ACTH inhibitor;
corticosteroid inhibitor;
|
- 1043. antiDNA autoantibody
- [autoimmune, pathological antibodies against histones, DNA, nuclear RNA, or other components of the cell nucleus. ( CSP )] (UMLS (CSP) C0003243) =Amino Acid, Peptide, or Protein; Immunologic Factor
| - 1093. antihypercholesterolemic agent
- [agents which reduce or control high cholesterol and bring about lower cholesterol levels in both the blood and the liver. ( CSP )] (UMLS (CSP) C0003277) =Pharmacologic Substance ;
|
- 1044. antidote
- [agent counteracting or neutralizing the action of a poison. ( CSP )] (UMLS (CSP) C0003295) =Pharmacologic Substance ;
| - 1094. antihyperglycemic
- [class of agents which lower blood glucose levels. ( CSP )] (UMLS (CSP) C0020616) =Pharmacologic Substance =Drug;
=1,1-Dimethylbiguanide;
sulfonylurea;
5-[[4-[4(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl\-2,4-thiazolidinedione;
Rosiglitazone;
insulinlike factor;
|
- 1045. antidromic impulse
- [neural impulse conducted in the opposite direction to normal. ( CSP )] (UMLS (CSP) C0178482) =Organ or Tissue Function =neural conduction;
| - 1095. antihyperkinetic agent
- [ ] (UMLS (CSP) C0596111) =Pharmacologic Substance ;
|
- 1046. antiemetic support
- (UMLS (NCI) C0279035) =Therapeutic or Preventive Procedure
| - 1096. antihypertensive agent
- [agent that reduces high blood pressure. ( CSP )] (UMLS (CSP) C0003364) =Pharmacologic Substance
|
- 1047. antiepileptic
- [ ] (UMLS (CSP) C0003299) =Pharmacologic Substance ;
| - 1097. antiinfective agent
- [substances that kill or prevent the spreading of infectious agents or organisms in order to prevent the spread of infection. ( CSP )] (UMLS (CSP) C0003204) =Pharmacologic Substance ;
|
- 1048. Antiestrogen
- [A substance that blocks the activity of estrogens, the family of hormones that promote the development and maintenance of female sex characteristics. ( NCI )] (UMLS (NCI) C0014930) =Pharmacologic Substance =hormone antagonist;
=1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene;
[6-Hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone | - 1098. antiinflammatory agent
- [agent that counteracts or suppresses the inflammatory process. ( CSP )] (UMLS (CSP) C0003209) =Pharmacologic Substance ;
|
- 1049. Antiestrogen Therapy
- (UMLS (NCI) C0854638) =Therapeutic or Preventive Procedure ;
| - 1099. antileukemic agent
- [substance that inhibits the development of or prevents leukemia. ( CSP )] (UMLS (CSP) C0596112) =Pharmacologic Substance ;
=[AN000] ANTINEOPLASTICS;
|
- 1050. antifibrinolytic agent
- [agents that prevent fibrinolysis or lysis of a blood clot or thrombus; several endogenous antiplasmins are known; these agents are used to control massive hemorrhage and in other coagulation disorders. ( CSP )] (UMLS (CSP) C0003304) =Pharmacologic Substance ;
| - 1100. antileukocyte isoantibody
- [ ] (UMLS (CSP) C0596113) =Amino Acid, Peptide, or Protein; Immunologic Factor =isoantibody;
|
home
